Drawing for GIBSON ONCOLOGY

USPTO serial 88097639

GIBSON ONCOLOGY

Reviewed by CopyMark Law Group

Reg. 5738919Status 702Registered
Filing date
Status date
Registration date
Apr 30, 2019
Examiner
BAL, KAMAL SINGH
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with GIBSON ONCOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kevin M. Bovard

Kevin M. Bovard BAKER & HOSTETLER LLP1735 Market StreetSuite 3300Philadelphia, PA 19103-7501

Goods and services

ClassDescriptionStatusFirst use
042Research and development services performed for others in the fields of drug discovery, drug discovery products, pharmaceuticals, medicinal diagnostics, and biological products; product development consultation in the field of pharmaceutical and biological productsACTIVEAug 21, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 6, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Nov 6, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 5, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 16, 2024E815TEAS SECTION 8 & 15 RECEIVED—
May 13, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 13, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 13, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 13, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 13, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 30, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Apr 30, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 12, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 12, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 23, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 7, 2019ALIEASSIGNED TO LIE—
Dec 12, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 12, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Dec 12, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 12, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 12, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 12, 2018DOCKASSIGNED TO EXAMINER—
Sep 8, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Sep 7, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 1, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance